[ Inside the business ]

BSX stock analysis

BSX · Boston Scientific Corp

Surgical and medical instruments and apparatus. Growing 1%. Keeps 19¢ of every dollar.

Watch: a leadership change, growth that has stopped speeding up.

The future, in 7 questions

Priced in: 1.2× sales in 5 yrs. Evidence: sales +1% · 19¢ profit/$1.

01 What's priced in?1.2× sales in 5 yrs
Sales now$21.1B
Needed in 5 yrs$24.5B
02 Is the wave rising?Neurotechnology · 0.9×
'20'21'22'23'24'2542
#4 of 20 mentioning it
03 Will customers keep buying?Sales +1%, slowing
No customer over 10%
Prepaid $711MSales +1%, slowing
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 19¢ per $1, rising
'21'22'23'24'2519¢
Before running costs: 69% → 69%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +1.1%/yrDebt $1B
07 What could break it?2 to watch
  • Growth slowing
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +12%, +8%, then +1% vs. a year ago. A leadership change was filed on Nov 17.

What could go wrong

Steadier than most.

It has moved 0.7× the market. In the 2008 crisis it fell 49% while the market fell 51%. Debt is moderate.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

19¢ profit.

31¢ to make what it sells, 50¢ on research and overhead, 19¢ left over. Revenue $21.1B in the last 12 months.

Its market

0.3× the economy.

The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

5 of 10 years.

Returns beat its 7.3% cost of capital in 5 of the last 10 years. Gross margin went from 66% to 69%.

Future bets

10% on research.

$2.2B a year on R&D. $903M on equipment and buildings.

All figures from Boston Scientific Corp's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.